Package Leaflet: Information for the User
Ropsine5 mg/ml solution for injection EFG
Ropivacaine hydrochloride
Read all of this leaflet carefully before you start using this medicine.
Contents of the pack:
Ropsine contains the active substance ropivacaine hydrochloride, which belongs to a class of medicines called local anesthetics.
Ropsine is used in adults to numb(anesthetize) the area of the body where surgery is to be performed. It is injected into the lower part of the spine. This quickly stops pain from the waist down for a limited period (usually 1 to 2 hours). This is known as a "spinal block" (or "spinal").
Ropsine is used in children aged 1-12 years to numb (anesthetize) parts of the body. It is used to calm pain or to relieve pain.
Do not useRopsine
Warnings and precautions
Talk to your doctor or pharmacist before you start using Ropsine
Special care should be taken to avoid any injectionof Ropsine directly into a blood vesselto prevent any immediate toxic effect. The injection should not be performed in an inflamed area.
Tell your doctor:
Tell your doctor if you have any of these problems as your doctor will need to adjust your dose of Ropsine.
Tell your doctor:
Tell your doctor if you or a family member has porphyria as your doctor may need to use a different anesthetic.
Using Ropsine with other medicines
Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines.
Caution should be taken if you are receiving:
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine. It is not known if ropivacaine hydrochloride affects pregnancy or if it passes into breast milk.
Children
Intrathecal administration (injection into the lower part of the spinal cord) has not been studied in infants or children under 12 years.
Driving and using machines
Ropsine may cause drowsiness and affect your reaction speed. Do not drive or use tools or machines after taking Ropsine, until the next day.
Ask your doctor or pharmacist if you have any doubts.
Important information about some of the ingredients of Ropsine
This medicine contains 3.2 mg of sodium (main component of cooking/table salt) per ml. This is equivalent to 0.2% of the maximum recommended daily intake of sodium for an adult.
Method of administration
Ropsine will be administered to you by your doctor. It will be given to you by injection.
Dose
The recommended dose will depend on what it is being used for and also on your health, age, and weight.
The smallest dose that can produce a numbing effect (anesthesia) of the required area should be used.
The usual dose
Duration of treatment
The administration of ropivacaine hydrochloride usually lasts between2 and 6 hoursin the case of anesthesiabefore certain surgeries.
It is administered by injection into the lower part of the spinal cord (intrathecal administration).
If you are given too much Ropsine
The first symptoms of being given too much ropivacaine hydrochloride are usually problems related to:
These symptoms may precede a heart attack, respiratory arrest, or severe seizures.
If you experience any of these symptoms or think you may have been given too much Ropsine, tell your doctor or healthcare staff immediately.
In case of acute toxicity, the appropriate corrective measures will be taken immediately by healthcare staff.
Due to the low dose administered during injection into the lower part of the spinal cord (intrathecal administration), it is not expected that side effects affecting the whole body will occur.
If you have any further questions on the use of this product, ask your doctor or pharmacist.
Like all medicines, Ropsine can cause side effects, although not everybody gets them.
Important side effects to look out for:
Sudden and potentially life-threatening allergic reactions (e.g. anaphylaxis, including anaphylactic shock) are rare and affect 1 to 10 people in 10,000. Possible symptoms include:
If you think you are having an allergic reaction to Ropsine, tell your doctor or healthcare staff immediately.
Other possible side effects:
Very common(may affect more than 1 in 10 people)
Common(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people)
Rare(may affect up to 1 in 1,000 people)
Side effects that have been reported with other local anesthetics that may also be caused by Ropsine include:
Additional side effects in children
In children, the side effects are the same as in adults, except for low blood pressure, which is less common in children (affecting less than 1 in 10 children), and feeling sick, which is more common in children (affecting more than 1 in 10 children).
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Spanish Medicines Agency's website: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use Ropsine after the expiry date which is stated on the ampoule or carton. The expiry date is the last day of the month stated.
Do not freeze.
Do not use Ropsine if you notice any precipitation in the solution for injection.
Normally, your doctor or hospital will store Ropsine and are responsible for the quality of the product if it is not used immediately after opening. They are also responsible for disposing of any unused Ropsine correctly.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Composition ofRopsine
Appearance of the Product and Container Contents
Ropsine injectable solution is a clear, colorless, sterile, isotonic, isobaric aqueous solution.
Ropsine 5 mg/ml injectable solution EFG is available in 10 ml transparent polypropylene ampoules.
Container size:
10 sterile ampoules in a plastic blister pack.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder:
Sintetica GmbH
Albersloher Weg 11
48155 Münster
Germany
Manufacturer:
Sintetica GmbH
Albersloher Weg 11
48155 Münster
Germany
Date of Last Revision of this Leaflet:September 2023.
Detailed and updated information on this medicinal product is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/.
-----------------------------------------------------------------------------------------------------------------------
This information is intended solely for doctors or healthcare professionals:
Handling
Ropsine should be used by, or under the supervision of, experienced physicians in regional anesthesia (see section 3)
Open by twisting the top of the ampoule sharply.
The ampoules are suitable for both Luerfit and LuerLock syringes.
Shelf Life before Opening
3 years
Shelf Life after Opening
From a microbiological point of view, the product should be used immediately. If not used immediately, the storage conditions during use and before administration are the responsibility of the user and generally should not exceed 24 hours at 2-8°C.
Ropsine medicines are preservative-free products intended for single use. Discard any unused solution.
The medicinal product should be inspected visually before use. The solution should only be used if the solution is clear, practically free of particles, and if the container is intact.
The intact container should not be re-introduced into the autoclave.
Posology
Adults and adolescents over 12 years of age
The table below is a guide to the most commonly used doses in different types of block. The smallest dose required to produce an effective block should be used. Clinical experience and knowledge of the patient's clinical condition are important factors in deciding the dose.
Indication | Concentration mg/ml | Volume ml | Dose mg | Onset of Action minutes | Duration hours |
Surgical Anesthesia | |||||
Intrathecal Administration | |||||
Surgery | 5.0 | 3-5 | 15-25 | 1-5 | 2-6 |
The doses shown in the table are those considered necessary to produce an adequate block and should be considered as recommendations for use in adults. There are individual variations in the onset and duration of action. The figures in the "Dose" column reflect the average dose range expected. Adequate literature should be consulted for factors affecting specific block techniques and the requirements of each patient. |
Dose foruse in infants from 1 yearand children up to12 years.Intrathecal administration has not been investigated in infants or children.
Concentration | Volume | Dose (mg/kg) | |
ACUTE PAIN TREATMENT (pre- and post-operative) | |||
Single InjectionforPeripheral Nerve Block(for exampleilioinguinal nerve block,brachial plexus block) | 5.0 mg/ml | 0.5 – 0.6 ml/kg | 2.5 – 3.0 mg/kg |
Continuous InfusionforPeripheral Nerve Block1 | 2.0 mg/ml | 0.1 – 0.3 ml/kg/h | 0.2 – 0.6 mg/kg/h |
1 Recommended duration of infusion was up to 72 hours |
Method of Administration
Intrathecal injection.
Before and during injection, careful aspiration is recommended to prevent intravascular injection. Accidental intravascular injection can be recognized by a temporary increase in heart rate.
Aspiration should be performed before and during administration of the main dose, which should be injected slowly at a rate of 25-50 mg/minute, while constantly monitoring the patient's vital functions and maintaining verbal contact with them. If toxic symptoms appear, administration of the medicinal product should be interrupted immediately.
Intrathecal injection will be performed once the subarachnoid space has been identified and the clear cerebrospinal fluid (CSF) is observed coming out of the spinal needle, or detected by aspiration.
Incompatibilities
No compatibility with other solutions has been investigated, so this medicinal product should not be mixed with other medicinal products.
Precipitation may occur in alkaline solutions since ropivacaine hydrochloride shows poor solubility at pH > 6.0.
Elimination
Elimination of unused medicinal products and all materials that have come into contact with them should be carried out in accordance with local regulations.